Evidence map›Paper›PMID 42353013›Full record

ReviewInternational journal of molecular sciences2026

Critical Overview of Molecular Insights into Osteoarthritis and Therapeutic Targets: Cytokines, RANKL, MMPs, Adipokines and Phosphate Dysregulation.

Mikołaj Bugajewski, Artur Stolarczyk, Maja Matysek, Jakub Piotr Adamus, Aleksandra Poszytek, Leszek Pączek

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mikołaj BugajewskiClinical Immunology Student Scientific Association, Medical University of Warsaw, Nowogrodzka 59, 02-006 Warsaw, Poland.ORCID 0009-0009-8043-0716
Artur StolarczykDepartment of Orthopedics and Rehabilitation, Medical University of Warsaw, 02-091 Warsaw, Poland.ORCID 0000-0002-5633-8153
Maja MatysekClinical Immunology Student Scientific Association, Medical University of Warsaw, Nowogrodzka 59, 02-006 Warsaw, Poland.
Jakub Piotr AdamusClinical Immunology Student Scientific Association, Medical University of Warsaw, Nowogrodzka 59, 02-006 Warsaw, Poland.ORCID 0009-0001-3142-9892
Aleksandra PoszytekClinical Immunology Student Scientific Association, Medical University of Warsaw, Nowogrodzka 59, 02-006 Warsaw, Poland.ORCID 0009-0006-0086-6228
Leszek PączekDepartment of Clinical Immunology, Medical University of Warsaw, 02-006 Warsaw, Poland.ORCID 0000-0003-0160-3009

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteoarthritis (OA) is a highly prevalent joint disorder traditionally considered a consequence of mechanical cartilage wear; however, it is now recognized as a complex, multifactorial disease driven by interconnected molecular and cellular mechanisms. This narrative review synthesizes current knowledge on key pathogenic pathways underlying OA progression, with a focus on inflammatory signaling, subchondral bone remodeling, and dysregulation of mineral metabolism. Chronic low-grade inflammation promotes catabolic responses in chondrocytes and contributes to cartilage degradation. In addition, obesity influences OA pathogenesis through both biomechanical loading and adipokine-mediated inflammatory mechanisms. Alterations in the receptor activator of nuclear factor kappa-B/receptor activator of nuclear factor kappa-B ligand/osteoprotegerin (RANK/RANKL/OPG) axis disrupt bone homeostasis and promote pathological subchondral remodeling, while imbalances in inorganic phosphate metabolism contribute to crystal deposition and further joint damage. These processes interact synergistically, driving disease progression. Current therapeutic strategies remain largely symptomatic and do not adequately target underlying molecular drivers. A deeper understanding of these mechanisms may facilitate the development of disease-modifying therapies.

Indexed as

AdipokinesCytokinesMatrix MetalloproteinasesOsteoarthritisPhosphatesRANK LigandAnimalsBone RemodelingHumansOsteoprotegerinSignal TransductionAdipokinesCytokinesMatrix MetalloproteinasesOsteoprotegerinPhosphatesRANK LigandADAMTSadipokinesbasic calcium phosphate crystalscytokinesmatrix metalloproteinasesobesityosteoarthritispyrophosphate (PPi)RANK/RANKL/OPGsubchondral bone remodeling

Identifiers

PMID42353013
PMCPMC13299590

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.